It came in just under the lower end of analyst expectations. While the result is great in its on right, it's still below expectation.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025